Status:

COMPLETED

An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)

Lead Sponsor:

Novartis

Conditions:

Chronic Obstructive Pulmonary Disease

Eligibility:

All Genders

40-80 years

Phase:

PHASE2

Brief Summary

This study evaluated the effect of QAB149 on dynamic and static hyperinflation, breathlessness, and health status in COPD patients

Eligibility Criteria

Inclusion

  • Male and female subjects,
  • 40 to 80 years of age,
  • with a documented diagnosis of mild, moderate or severe chronic obstructive pulmonary disease (COPD) according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria and \>20-pack year history of smoking, a post-bronchodilator 40% ≤ FEV1 ≤ 80% of predicted normal and post-bronchodilator FEV1/FVC \< 70% who have signed an informed consent form (ICF) prior to the initiation of any study-related procedure (Post bronchodilator refers to 30 minutes after the inhalation of 400 µg of salbutamol)
  • Subjects who demonstrate a plethysmographic functional residual capacity \>120% predicted normal

Exclusion

  • No COPD exacerbations within 6 weeks prior to dosing,
  • no concomitant lung disease such as asthma,
  • no requirement for long term oxygen treatment or history of lung reduction surgery.
  • No medical conditions that would interfere with the performance of spirometry or clinical exercise testing.
  • Any other medical condition that in the opinion of the investigator may cause the patient to be unsuitable for completion of the study or place the patient at potential risk from participating in the study e.g. uncontrolled hypertension or unstable ischemic heart disease
  • Other protocol-defined inclusion/exclusion criteria may apply

Key Trial Info

Start Date :

February 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2008

Estimated Enrollment :

27 Patients enrolled

Trial Details

Trial ID

NCT00636961

Start Date

February 1 2008

End Date

August 1 2008

Last Update

August 30 2011

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Novartis Investigator Site

Berlin, Germany

2

Novartis Investigator Site

Mönchengladbach, Germany

3

Novartis Investigator Site

Wiesbaden, Germany

An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD) | DecenTrialz